Skip to Content

'
Sean M. Post, PHD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 University of Texas Health Science Center at San Antonio, San Antonio, TX, PHD, Molecular Medicine
1996 University of Arkansas at Little Rock, Little Rock, AR, BS, Biology

Postgraduate Training

8/2004-7/2011 Postgraduate Training, University of Texas MD Anderson Cnacer Center, Houston, TX, Guillermina Lozano
10/2003-8/2004 Postgraduate Training, Baylor College of Medicine, Houston, TX, Vicki Lundblad

Experience/Service

Academic Appointments

Member of Faculty, Division of Basic Science Research, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2011-present

Military or Other Governmental Service

Sergeant, United States Army, 10/1989-1/1997

Honors and Awards

2005 Dodie P. Hawn Fellowship in Cancer Genetics, UT MD Anderson Cancer Center
2001 11th Annual Symposia on Cancer Research in San Antonio, San Antonio Cancer Institute
2001 Department of Molecular Medicine/Institute Biotechnology Annual Retreat, Institute Biotechnology

Professional Memberships

American Society Of Hematology
Member, 5/2012
The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
Member, 9/2012-8/2013

Selected Publications

Peer-Reviewed Original Research Articles

1. Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 118(21):5283-92, 11/2012. e-Pub 4/2012. PMCID: PMC3435477.
2. Lee HJ, Zhang X, Attie Y, Post SM. Knowing is Half the Battle in the Genetics of Acute Myelogenous Leukemia. Genetic Syndromes & Gene Therapy 112(3), 5/2012.
3. Post SM. Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res 2(1):20, 2012. e-Pub 10/2012. PMCID: PMC3499229.
4. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Res 71(23):7168-75, 12/2011. e-Pub 10/2011. PMID: 21983037.
5. Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 223(2):127-36, 1/2011. e-Pub 10/2010. PMID: 20957626.
6. Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol 222(2):124-8, 10/2010. PMID: 20821751.
7. Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcoms. Journal of Pathology. Journal of Pathology 222(2):124-8, 10/2010.
8. Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell(3):220-230, 9/2010.
9. Xiong S, Pant V, Suh YA, Van Pelt C, Wang Y, Valentin-Vega Y, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing Mdm4. Cancer Research 70(18):7148-54, 9/2010.
10. Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM , Lozano G. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70(18):7148-54, 9/2010. e-Pub 8/2010. PMCID: PMC2940952.
11. Post SM, Pant V, Abbas H, Quintás-Cardama A. Prognostic impact of the MDM2SNP309 allele in hematologic malignancies. Oncotarget 1(3):168-174, 7/2010.
12. Post SM , Pant V, Abbas H, Quintás-Cardama A. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma. Oncotarget 1(3):168-74, 7/2010. PMCID: PMC3157715.
13. Post, SM, Quintás-Cardama A. Closing in on the pathogenesis of the 5q- syndrome. Expert Rev Anticancer 10(5):655-8, 5/2010.
14. Fang S, Krahe R, Lozano G, Han Y, Chen W, Bachinski LL, Post SM, Wilson C, Strong LC, Amos CI. The effect of Mdm2 and p53 codon72 polymorphisms on cancer risk in p53 germline mutation carriers. PLoS One 5(5), 5/2010.
15. Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Eu-myc induced B-cell lymphomagenesis. Oncogene 29(9):1260-9, 4/2010.
16. Martinez LA, Goluszko E, Chen H-Z, Leone G, Post SM, Lozano G, Chen Z, Chauchereau A. E2F3a is a Mediator of DNA Damage Induced Apoptosis. Mol. Cell. Bio 30(2):524-36, 1/2010.
17. Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5(5):e10813, 2010. e-Pub 5/2010. PMCID: PMC2877078.
18. Song W, Levin DS, Varkey J, Post SM, Bermudez VP, Hurwitz J, Tomkinson AE. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Development 22(10):1337-44, 5/2008.
19. Song W, Levin DS, Varkey J, Post SM, Bermudez VP, Hurwitz J, Tomkinson AE. A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes. J. Biol. Chem 282(31):22721-30, 8/2007.
20. Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol 24(4):768-74, 4/2004. e-Pub 2/2004. PMID: 14962946.
21. Motycka TA, Bessho T, Post, SM, Sung P, Tomkinson AE. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J. Biol. Chem. 279(14):13634-9, 1/2004.
22. Post SM, Lee EY. Detection of kinase and phosphatase activities. Methods Mol Biol 241:285-97, 2004. PMID: 14970662.
23. Post SM, Tomkinson AE, Lee E. The human checkpoint protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase. Nucleic Acids Research 31(19):5568-5575, 10/2003.
24. Post SM, Tomkinson AE, Lee EY. The human checkpoint Rad protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase epsilon. Nucleic Acids Res 31(19):5568-75, 10/2003. PMCID: PMC206465.
25. Post SM, Weng YC, Cimprich K, Chen LB, Xu Y, Lee E. Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G1/S checkpoint activation in response to DNA damage. Proc. Natl. Acad. Science 98(23):13102-13107, 6/2001.

Book Chapters

1. Post SM, Quintas-Cardama A, Lozano G. Regulation of p53 Activity and Associated Checkpoint Controls. In: Checkpoint Controls and Targets in Cancer Therapy, Cancer Drug Discover and Development. In: Humana Press Inc. 29, 9, 1260-1269, 2010.

Grant & Contract Support

Title: hnRNP K:a novel biomarker leukemia and regulator of hematopoietic differentiation
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Sean Post, PhD
Duration: 9/1/2013 - 8/31/2018
 
Title: ASH Scholar in Basic/Translational Research Junior Faculty: Evaluating the impact of aberrant hnRNP K expression on the p53 pathway and AML progression
Funding Source: American Society of Hematology (ASH)
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2016
 
Title: New Approaches to the Biology and Treatment of MDS Project 3: Innate Immunity Alterations in MDS
Funding Source: NIH/NHLBI
Role: Co-Investigator
Principal Investigator: Guillermo Garcia-Manero, MD
Duration: 5/1/2013 - 4/30/2018
 
Title: Nucleophosmin Mutations Disrupt Normal p53 Activities In AML
Funding Source: American Cancer Society (ACS)
Role: Co-Investigator
Principal Investigator: Hun Ju Lee, M.D.
Duration: 1/1/2013 - 12/31/2017
 
Title: Evaluating the impact of a putative regulator of the p53 pathway
Funding Source: Rita Allen Foundation
Role: Principal Investigator
Duration: 9/1/2012 - 8/31/2017
 
Title: Evaluation of biomarkers for CLL progression in the p53 pathway: a genetic approach in mice and man
Funding Source: Lymphoma Research Foundation
Role: Principal Investigator
Duration: 7/15/2012 - 7/14/2014
 
Title: Evaluating the impact of hnRNP K expression on the p53 pathway and in tumorigenesis
Funding Source: Sidney Kimmel Foundation
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2014
 
Title: A regulator of p53 function influences tumor formation and leukemogenesis
Funding Source: Ladies Leukemia League
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2013
 
Title: CDP: Evaluating the impact of aberrant hnRNP K expression on the p53 pathway and AML
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/1/2012 - 4/30/2013
 
Title: Evaluating the Impact of Mdm2SNP309 in Colon Cancer
Funding Source: Center for Genetics and Genomics
Role: Principal Investigator
Duration: 9/15/2011 - 8/31/2012
 
Title: The role of Mdm2SNP 309 in CLL
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/23/2011 - 4/30/2013
 
Title: A polymorphism in the Mdm2 promoter enhances cancer risk
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/20/2006 - 8/19/2007
 
Title: Phosphorylation of human Rad17 by ATR is required for cell cycle checkpoint activation
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 4/1/2002 - 3/31/2004

Last updated: 4/30/2013